Protalix BioTherapeutics, Inc. reported a total revenue of $43.6 million for the nine months ended September 30, 2025, marking a 24% increase from $35.2 million in the same period of the previous year. The revenue growth was primarily driven by a $4.5 million increase in sales to Chiesi and a $4.0 million increase in sales to Pfizer, although this was partially offset by a slight decrease in sales to Fiocruz in Brazil. The company recorded a net loss of $1.1 million for the nine-month period, an improvement compared to a net loss of $3.6 million for the same period in 2024. Basic and diluted loss per share for the nine months ended September 30, 2025, was $(0.01), compared to $(0.05) for the prior year.
In terms of operational metrics, Protalix's cash and cash equivalents decreased to $13.6 million as of September 30, 2025, down from $19.8 million at the end of 2024. The company’s total assets increased to $82.3 million, up from $73.4 million at the end of the previous fiscal year, largely due to an increase in accounts receivable. Total liabilities decreased to $29.4 million from $30.2 million, reflecting a reduction in current liabilities. The company’s stockholders' equity rose to $52.9 million, compared to $43.2 million at the end of 2024, indicating a strengthening balance sheet.
Strategically, Protalix has made significant advancements in its product pipeline, including the recent submission of an Investigational New Drug (IND) application for PRX-115, a treatment for uncontrolled gout, which has become effective following the FDA's standard review period. The company is also preparing for a Phase 2 clinical trial of PRX-115, expected to commence in the fourth quarter of 2025. Additionally, Protalix has continued to enhance its ProCellEx technology platform, which is integral to its product development efforts.
The company has also experienced changes in its management structure, with Gilad Mamlok succeeding Eyal Rubin as Senior Vice President and Chief Financial Officer as of August 24, 2025. Furthermore, Protalix is actively exploring strategic partnerships and collaborations to bolster its market position and expand its product offerings. The company remains focused on addressing unmet medical needs in rare and orphan diseases, leveraging its proprietary technology to develop innovative therapies.
Looking ahead, Protalix anticipates continued investment in research and development, particularly as it advances its clinical trials and product candidates. The company believes that its current cash reserves and short-term bank deposits are sufficient to meet its capital needs for at least the next 12 months. However, it acknowledges the potential need for additional financing to support its ongoing operations and development activities, particularly as it seeks to commercialize its products and expand its market presence.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics is a biopharmaceutical company specializing in developing, manufacturing, and commercializing recombinant therapeutic proteins using its proprietary plant cell-based ProCellEx platform. Its core products include enzyme replacement therapies for rare diseases like Fabry and Gaucher. The company focuses on innovative treatments for high unmet medical needs, leveraging unique plant-based production methods to enhance safety, efficacy, and manufacturing flexibility.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.